{"generic":"Strontium Ranelate","drugs":["Strontium Ranelate"],"mono":{"0":{"id":"930373-s-0","title":"Generic Names","mono":"Strontium Ranelate"},"1":{"id":"930373-s-1","title":"Dosing and Indications","sub":[{"id":"930373-s-1-4","title":"Adult Dosing","mono":"<ul><li>strontium ranelate has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Osteoporosis, Severe, in men at increased risk of fracture:<\/b> 2 g (1 sachet) ORALLY once daily at bedtime; ensure adequate calcium and vitamin D intake (European Medicines Agency-approved dosing)<\/li><li><b>Postmenopausal osteoporosis, Severe, in women at high risk for fracture:<\/b> 2 g (1 sachet) ORALLY once daily at bedtime; ensure adequate calcium and vitamin D intake (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930373-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients less than 18 years old "},{"id":"930373-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, severe (CrCl, less than 30 mL\/min):<\/b> use not recommended<\/li><li><b>renal impairment, mild-to-moderate (CrCl, 30 to 70 mL\/min):<\/b> no dosage adjustment required<\/li><li><b>hepatic impairment:<\/b> no dosage adjustment required<\/li><li><b>elderly:<\/b> no dosage adjustment required<\/li><\/ul>"},{"id":"930373-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Osteoporosis, Severe, in men at increased risk of fracture<\/li><li>Postmenopausal osteoporosis, Severe, in women at high risk for fracture<\/li><\/ul>"}]},"3":{"id":"930373-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930373-s-3-9","title":"Contraindications","mono":"<ul><li>cerebrovascular disease, current or history of<\/li><li>hypersensitivity to strontium ranelate or any component of the product<\/li><li>immobilization, temporary or permanent (eg, postsurgical recovery, prolonged bed rest)<\/li><li>ischemic heart disease, current or history of<\/li><li>peripheral arterial disease, current or history of<\/li><li>uncontrolled hypertension<\/li><li>VTE, current or history of, including DVT or pulmonary embolism<\/li><\/ul>"},{"id":"930373-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>--myocardial infarction has been reported in postmenopausal women; baseline screening and monitoring recommended; discontinuation may be required<\/li><li>-- VTE has been reported; treat at-risk patients with caution and interrupt treatment with onset of immobility; discontinue if condition occurs<\/li><li>-- treatment of patients with significant cardiovascular risk factors (eg, smoking, diabetes, hyperlipidemia, hypertension) warrants special caution; monitoring recommended; discontinuation may be required<\/li><li>-- uncontrolled hypertension, ischemic heart disease, or peripheral vascular disease; discontinue if conditions occur<\/li><li>Dermatologic Effects:<\/li><li>-- life-threatening cutaneous reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms may rarely occur, with increased risk among Asian patients; monitoring recommended and immediate discontinuation required if condition is suspected<\/li><li>Neurologic:<\/li><li>-- cerebrovascular disease; discontinue if condition occurs<\/li><li>Renal Effects:<\/li><li>-- not recommended for patients with severe renal impairment (ie, CrCl less than 30 mL\/min); discontinuation may be required if severe renal impairment develops during therapy<\/li><li>-- monitoring recommended in patients with chronic renal impairment<\/li><li>Respiratory Effects:<\/li><li>-- pulmonary embolism has been reported; treat at-risk patients with caution and interrupt treatment with onset of immobility; discontinue if condition occurs<\/li><li>Other:<\/li><li>-- reassess need for continued treatment in elderly patients (ie, over 80 years of age) at risk for VTE<\/li><li>-- drug contains phenylalanine, which may harm patients with phenylketonuria<\/li><li>Concomitant Use:<\/li><li>-- do not coadminister with oral tetracyclines (eg, doxycycline) or quinolone antibiotics (eg, ciprofloxacin)<\/li><li>-- coadministration with calcium-containing food and supplements at the same time may decrease absorption; separate administration by 2 or more hours<\/li><\/ul>"},{"id":"930373-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930373-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930373-s-4","title":"Drug Interactions","sub":{"2":{"id":"930373-s-4-15","title":"Moderate","mono":"<ul>Calcium (probable)<\/ul>"}}},"5":{"id":"930373-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Eczema (1% to less than 10%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea (1% to less than 10%)<\/li><li><b>Musculoskeletal:<\/b>Increased creatine kinase level (1% to less than 10%), Musculoskeletal pain (10% or greater)<\/li><li><b>Neurologic:<\/b>Amnesia (1% to less than 10%), Disturbance of consciousness (1% to less than 10%), Headache (1% to less than 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction (1.7%), Venous thromboembolism (1% to less than 10%)<\/li><li><b>Dermatologic:<\/b>Drug hypersensitivity syndrome, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Neurologic:<\/b>Seizure (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Asthma (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"930373-s-6","title":"Drug Name Info","sub":{"2":{"id":"930373-s-6-19","title":"Class","mono":"Musculoskeletal Agent<br\/>"},"3":{"id":"930373-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930373-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>suspend granules in at least 30 mL of water and drink immediately<\/li><li>do not take with food or milk<\/li><li>take at bedtime, preferably at least 2 hours after eating<\/li><li>calcium and vitamin D supplementation recommended if dietary intake insufficient<\/li><\/ul>"},"10":{"id":"930373-s-10","title":"Monitoring","mono":"<ul><li>Lowered incidence of osteoporotic fractures is indicative of efficacy.<\/li><li>cardiovascular risk, before treatment initiation and every 6 to 12 months<\/li><li>renal function, periodically in patients with chronic renal impairment<\/li><li>VTE risk; reevaluate continued treatment in patients over 80 years of age at risk for VTE<\/li><\/ul>"}}}